ArticleJTCVS open2026
An early nationwide analysis on the continuous distribution of lung-involved multiorgan transplantation.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Survival and Outcomes of Lung-Kidney and Lung-Liver Transplants Using a Large National Cohort.Clinical transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The impact of continuous distribution on allocation of multiorgan transplantation (MOT) involving lungs remains unexplored. Here we characterize how continuous distribution has affected lung-involved MOT. Methods: We conducted a retrospective study using the United Network for Organ Sharing database. Adults listed for lung-MOT between March 9, 2021, and March 8, 2025, were included. The lung allocation score (LAS) era included the 24 months prior to March 9, 2023, and the composite allocation score (CAS) era comprised 24 months after March 9, 2023. Primary outcomes included transplantation rate, waitlist mortality, and 6-month composite outcome (graft rejection and death) assessed with Kaplan-Meier methods and Poisson regression to estimate transplantation rate and waitlist mortality. Post-transplantation survival was modeled using Cox proportional hazards. Results: Among 498 lung-MOT candidates listed for transplantation during the study period (274 heart-lung, 106 lung-liver, and 101 lung-kidney), 349 underwent transplantation (205 heart-lung, 77 lung-liver, and 60 lung-kidney). The transplantation rate per 100 patient-years increased significantly for all combinations under CAS (heart-lung, 90.5 vs 172.9; lung-liver, 57.9 vs 254.5; lung-kidney, 118.8 vs 194.2; Conclusions: The transition from LAS to CAS enhanced access to transplantation for lung-MOT, while waitlist mortality remained similar. Short-term post-transplant composite outcomes did not differ between eras, supporting the feasibility of CAS for lung-MOT candidates without negatively impacting early outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.